AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20478471 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (component of the triple antibiotic paste)
Number of subjects: 1
Study 20478471 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin bonding agent
Number of subjects: 1
Study 18521830 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrectomy due to incomplete ER and local recurrence after ER
Number of subjects: 86
Study 18521830 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrectomy specimens with submucosal invasion without margin involvement
Number of subjects: 86
Study 18521830 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrectomy specimens with margin involvement
Number of subjects: 86
Study 18521830 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with local recurrence
Number of subjects: 86
Study 15939717 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy with 5-Fluorouracil (5-FU) and cisplatin
Number of subjects: 260
Study 15939717 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 260
Study 11820861 — intervention group
Group type: EXPERIMENTAL
Intervention: Wine drinkers
Number of subjects: 3
Study 11820861 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirits drinkers
Number of subjects: 3
Study 11820861 — intervention group
Group type: COMPARATOR
Intervention: Teetotalers (Control)
Number of subjects: 3
Study 10403867 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced laryngeal mask airway
Number of subjects: 120
Study 10403867 — intervention group
Group type: COMPARATOR
Intervention: Standard laryngeal mask airway
Number of subjects: 120
Study 10403867 — intervention group
Group type: COMPARATOR
Intervention: Nasal mask
Number of subjects: 120
Study 7751410 — intervention group
Group type: EXPERIMENTAL
Intervention: Linopirdine (DuP 996) 0.5 to 55 mg in young subjects; 20 to 45 mg in elderly subjects
Number of subjects: 64
Study 7751410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 2148280 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose enoximone
Number of subjects: 30
Study 2148280 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose enoximone
Number of subjects: 30
Study 2148280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 359109 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 1 mg and 2 mg
Number of subjects: 80
Study 359109 — intervention group
Group type: COMPARATOR
Intervention: Meperidine 40 mg and 80 mg
Number of subjects: 80
Study 359109 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 80
Study 359109 — intervention group
Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 80
Study 359109 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol and Meperidine
Number of subjects: 80
Study 31222759 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolite-guided treatment approach
Number of subjects: 0
Study 31223148 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-minute workshop (Group B)
Number of subjects: 183
Study 31223148 — intervention group
Group type: COMPARATOR
Intervention: 30-minute lecture (Group A)
Number of subjects: 183
Study 31223148 — intervention group
Group type: COMPARATOR
Intervention: No training (Group C)
Number of subjects: 183
Study 27794631 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance Training (BT)
Number of subjects: 42
Study 27794631 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar Stabilization (LS)
Number of subjects: 42
Study 27794631 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-Oriented Training (TT)
Number of subjects: 42
Study 26069973 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet cupping therapy (6 sessions within 2 weeks at two bladder meridian acupuncture points)
Number of subjects: 80
Study 26069973 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 80
Study 23791771 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitising toothpaste (DT)
Number of subjects: 75
Study 23791771 — intervention group
Group type: EXPERIMENTAL
Intervention: Professionally applied dentine bonding agent (DA)
Number of subjects: 75
Study 23791771 — intervention group
Group type: COMPARATOR
Intervention: Non-desensitising toothpaste (NDT)
Number of subjects: 75
Study 21680999 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxy 5 mg twice daily (10 mg total daily oxycodone dose) for opioid-naïve patients; equivalent dose for opioid-experienced patients based on previous opioid daily dose.
Number of subjects: 823
Study 19265726 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (concentrated amino acid drink with no tryptophan)
Number of subjects: 27
Study 19265726 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 27
Study 16458545 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg/day)
Number of subjects: 30
Study 16458545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14713399 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 0
Study 14713399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclooxygenase-2 selective agents
Number of subjects: 0
Study 14713399 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0
Study 14713399 — intervention group
Group type: EXPERIMENTAL
Intervention: Western Ontario and McMaster Osteoarthritis Index
Number of subjects: 0
Study 11553420 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group received usual care plus individual and group sessions with an asthma nurse.
Number of subjects: 112
Study 11553420 — intervention group
Group type: COMPARATOR
Intervention: Control group received usual care only.
Number of subjects: 112
Study 9373758 — intervention group
Group type: EXPERIMENTAL
Intervention: 937 IU vitamin E (d1-alpha-tocopherol acetate)
Number of subjects: 16
Study 9373758 — intervention group
Group type: EXPERIMENTAL
Intervention: 432 IU vitamin E (d1-alpha-tocopherol acetate)
Number of subjects: 16
Study 7516450 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV/PE (cyclophosphamide, doxorubicin, vincristine alternating with cisplatin and etoposide)
Number of subjects: 351
Study 7516450 — intervention group
Group type: EXPERIMENTAL
Intervention: PE (cisplatin and etoposide)
Number of subjects: 351
Study 7516450 — intervention group
Group type: COMPARATOR
Intervention: CAV (cyclophosphamide, doxorubicin, vincristine)
Number of subjects: 351
Study 7516450 — intervention group
Group type: EXPERIMENTAL
Intervention: CODE plus G‐CSF (cyclophosphamide, Oncovin, doxorubicin, etoposide with granulocyte-colony stimulating factor)
Number of subjects: 351
Study 7516450 — intervention group
Group type: COMPARATOR
Intervention: CODE alone (cyclophosphamide, Oncovin, doxorubicin, etoposide)
Number of subjects: 351
Study 2887173 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg WAL 801 CL
Number of subjects: 9
Study 2887173 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg WAL 801 CL
Number of subjects: 9
Study 2887173 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 mg WAL 801 CL
Number of subjects: 9
Study 2887173 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg ketotifen
Number of subjects: 9
Study 2887173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29614659 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) levels measured by LAPAQ and activity monitor
Number of subjects: 121
Study 29614659 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise capacity measured against population normative data
Number of subjects: 121
Study 29614659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness
Number of subjects: 121
Study 27635789 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT (120 kVp, 45 mAs)
Number of subjects: 134
Study 27635789 — intervention group
Group type: COMPARATOR
Intervention: Standard dose CT (120 kVp, 100 mAs)
Number of subjects: 134
Study 24628076 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 25 mcg
Number of subjects: 43
Study 24628076 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 43
Study 24431884 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin syringe
Number of subjects: 40
Study 24431884 — intervention group
Group type: COMPARATOR
Intervention: Standard 3mL syringe
Number of subjects: 40
Study 21353107 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg/d or Naproxen 250 mg BID for 8 weeks
Number of subjects: 4101
Study 21353107 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg/d or Naproxen 250 mg BID for 6 months
Number of subjects: 4101
Study 21353107 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean postbaseline sUA concentration <6.0 mg/dL
Number of subjects: 4101
Study 21353107 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis duration
Number of subjects: 4101
Study 18275573 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone suppository (400 mg) daily until delivery
Number of subjects: 70
Study 18275573 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 70
Study 16187992 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear corneal phacoemulsification and foldable intraocular lens implantation
Number of subjects: 30
Study 16187992 — intervention group
Group type: COMPARATOR
Intervention: Control group (filtering surgery without cataract extraction)
Number of subjects: 30
Study 14969070 — intervention group
Group type: EXPERIMENTAL
Intervention: Early DMARD group (hydroxychloroquine, intramuscular gold, oral methotrexate)
Number of subjects: 0
Study 14969070 — intervention group
Group type: COMPARATOR
Intervention: Pyramid strategy group
Number of subjects: 0
Study 14969070 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX or iAU as the first DMARD
Number of subjects: 0
Study 14969070 — intervention group
Group type: EXPERIMENTAL
Intervention: iAU therapy
Number of subjects: 0
Study 10382188 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nutritional supplement between meals and at bedtime
Number of subjects: 40
Study 10382188 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutritional supplement)
Number of subjects: 40
Study 8694698 — intervention group
Group type: EXPERIMENTAL
Intervention: pyruvate-based peritoneal dialysis solution (pH 5.2)
Number of subjects: 6
Study 8694698 — intervention group
Group type: COMPARATOR
Intervention: lactate-based peritoneal dialysis solution (control)
Number of subjects: 6
Study 1702144 — intervention group
Group type: COMPARATOR
Intervention: ProMACE-MOPP
Number of subjects: 193
Study 1702144 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMACE-CytaBOM
Number of subjects: 193
Study 6341639 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhesus diploid‐cell‐strain rabies vaccine (RDRV)
Number of subjects: 60
Study 6341639 — intervention group
Group type: COMPARATOR
Intervention: Commercial high‐titer rabies immune globulin, 20 IU/kg
Number of subjects: 60
Study 6341639 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhesus diploid‐cell‐strain rabies vaccine (RDRV) without prior rabies immune globulin
Number of subjects: 60
Study 31062389 — intervention group
Group type: EXPERIMENTAL
Intervention: B2M mutant tumours (39 of 121, 32%)
Number of subjects: 121
Study 31062389 — intervention group
Group type: COMPARATOR
Intervention: B2M wild-type tumours (77 total, 14 recurred)
Number of subjects: 121
Study 31062389 — intervention group
Group type: COMPARATOR
Intervention: pMMR CRCs (108 total, 3 with deleterious B2M mutations)
Number of subjects: 121
Study 28788782 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantum-noise randomized cipher (QNRC) system
Number of subjects: 0
Study 28788782 — intervention group
Group type: EXPERIMENTAL
Intervention: QNRC combined with proper channel codes
Number of subjects: 0
Study 28788782 — intervention group
Group type: EXPERIMENTAL
Intervention: Secrecy of running key
Number of subjects: 0
Study 25493397 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6280 10 mg
Number of subjects: 16
Study 25493397 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6280 40 mg
Number of subjects: 16
Study 25493397 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 2 mg
Number of subjects: 16
Study 25493397 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6280
Number of subjects: 16
Study 23689789 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-initiated patient-directed music (PDM) (n = 126)
Number of subjects: 373
Study 23689789 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 125)
Number of subjects: 373
Study 23689789 — intervention group
Group type: COMPARATOR
Intervention: Noise-canceling headphones (NCH) (n = 122)
Number of subjects: 373
Study 21309709 — intervention group
Group type: EXPERIMENTAL
Intervention: Derris scandens Benth extracts 800 mg/day
Number of subjects: 107
Study 21309709 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg/day
Number of subjects: 107
Study 19930626 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus point of care prothrombin time testing
Number of subjects: 220
Study 19930626 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone without point of care testing
Number of subjects: 220
Study 16500386 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy (ES)
Number of subjects: 50
Study 16500386 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided sclerotherapy of collateral vessels (EUS-ES)
Number of subjects: 50
Study 15476993 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management program including an educational booklet, an initial 1-hour educational session, and scheduled supportive phone calls over 6 weeks.
Number of subjects: 25
Study 15476993 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management program
Number of subjects: 25
Study 11597664 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (62.5mg taken twice daily for 4 weeks then 125 mg twice daily)
Number of subjects: 32
Study 11597664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11597664 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 32
Study 9408514 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin 7 mg/kg i.v. once daily by itself
Number of subjects: 10
Study 9408514 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin with piperacillin 4 g and tazobactam 0.5 g every six hours i.v.
Number of subjects: 10
Study 9408514 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin with piperacillin 4 g and tazobactam 0.5 g every eight hours i.v.
Number of subjects: 10
Study 9408514 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin with piperacillin 8 g and tazobactam 1 g by continuous i.v. infusion over 24 hours
Number of subjects: 10
Study 7961338 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine at a dose of 0.6 mg/kg/day
Number of subjects: 16
Study 7961338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3328992 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety Management (self-help treatment including procedures for managing somatic and cognitive symptoms, avoidance, and low self-confidence)
Number of subjects: 0
Study 3328992 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group (control)
Number of subjects: 0
Study 29369074 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS with ECT
Number of subjects: 16
Study 29369074 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS with ECT
Number of subjects: 16
Study 28057390 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 16mg administered 60 minutes before surgery
Number of subjects: 90
Study 28057390 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 16mg administered 60 minutes after surgery
Number of subjects: 90
Study 28057390 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 60 minutes before surgery
Number of subjects: 90
Study 28057390 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 60 minutes after surgery
Number of subjects: 90
Study 26572860 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Early Supported Discharge (VESD) with home rehabilitation intervention from a coordinated team
Number of subjects: 10
Study 26572860 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Early Supported Discharge (VESD)
Number of subjects: 10
Study 23143621 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg thalidomide once/day
Number of subjects: 111
Study 23143621 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g sulfasalazine, twice/day
Number of subjects: 111
Study 23143621 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs for maintenance treatment
Number of subjects: 111
Study 21722168 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (0.7 mL, 10 units/mL)
Number of subjects: 88
Study 21722168 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.7 mL)
Number of subjects: 88
Study 18402253 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane (3.2% MACBAR in children 1-6 years)
Number of subjects: 28
Study 18402253 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane with fentanyl (2.2% MACBAR)
Number of subjects: 28
Study 18402253 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane (3.4% MACBAR in infants 6-12 months)
Number of subjects: 28
Study 16540702 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 136
Study 16540702 — intervention group
Group type: COMPARATOR
Intervention: Other SGA drugs
Number of subjects: 136
Study 14520254 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH-Sodium controlled diet
Number of subjects: 0
Study 14520254 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance processes
Number of subjects: 0
Study 10736383 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG) at a dose of 2500 mg
Number of subjects: 65
Study 10736383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 9363292 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (individualized dosing according to response and side effects)
Number of subjects: 13
Study 1313100 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg minocycline per day for 8 days
Number of subjects: 30
Study 1313100 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg minocycline per day for 8 days
Number of subjects: 30
Study 1313100 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 30
Study 4008643 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN) at a dose of 3 X 10(6) U
Number of subjects: 0
Study 4008643 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN) at doses of 3 X 10(6), 10(7), and 3 X 10(7) U
Number of subjects: 0
Study 4008643 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-injection PMC cultured overnight
Number of subjects: 0
Study 30839304 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep core stability exercise program plus traditional abdominal exercises, 3 times a week for 8 weeks
Number of subjects: 40
Study 30839304 — intervention group
Group type: COMPARATOR
Intervention: Traditional abdominal exercises, 3 times a week for 8 weeks
Number of subjects: 40
Study 29862507 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-Specs
Number of subjects: 40
Study 29862507 — intervention group
Group type: COMPARATOR
Intervention: Sham-Specs
Number of subjects: 40
Study 26525369 — intervention group
Group type: EXPERIMENTAL
Intervention: OFIRMEV 1 g every 6 hours for 24 hours
Number of subjects: 34
Study 26525369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 25252964 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyriform sinus localization-assisted blind intubation
Number of subjects: 300
Study 25252964 — intervention group
Group type: COMPARATOR
Intervention: Conventional laryngoscopic intubation
Number of subjects: 300
Study 22130164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab at 10 mg/kg every 3 weeks for 4 doses
Number of subjects: 115
Study 22130164 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (oral)
Number of subjects: 115
Study 22130164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 20176568 — intervention group
Group type: EXPERIMENTAL
Intervention: GFD with zinc supplementation for 4 weeks
Number of subjects: 134
Study 20176568 — intervention group
Group type: COMPARATOR
Intervention: GFD without zinc supplementation
Number of subjects: 134
Study 17272329 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) current supported extraction
Number of subjects: 120
Study 17272329 — intervention group
Group type: COMPARATOR
Intervention: Standard countertraction lead removal
Number of subjects: 120
Study 15617785 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain perfusion SPECT in patients with BPD and ASPD
Number of subjects: 37
Study 15617785 — intervention group
Group type: COMPARATOR
Intervention: Healthy control participants
Number of subjects: 37
Study 11828227 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg)
Number of subjects: 10
Study 11828227 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (400 microg)
Number of subjects: 10
Study 11828227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9952147 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 microg/kg
Number of subjects: 6
Study 9952147 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 microg/kg
Number of subjects: 6
Study 9952147 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 6
Study 8649928 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-1-antitrypsin (AAT), albumin and total protein in meconium and stools
Number of subjects: 0
Study 8649928 — intervention group
Group type: EXPERIMENTAL
Intervention: Total protein content
Number of subjects: 0
Study 8649928 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant determination of AAT, albumin and total protein in stool
Number of subjects: 0
Study 2297411 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery dissection
Number of subjects: 106
Study 2297411 — intervention group
Group type: COMPARATOR
Intervention: Cold dissection with selective cauterization
Number of subjects: 106